Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01478685 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 169
- Enrollment target
NCT01478685 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 169 participants.
The verdict
NCT01478685, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 169 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety and to define the Maximal Tolerated Dose (MTD) or the Maximal Administered Dose (MAD) of oral azacitidine as a single agent and in combination with carboplatin (CBDCA) or paclitaxel protein bound particles (ABI-007,ABX) in subjects with relapsed or refractory solid tumors.
Interventions
- DRUG Carboplatin
- DRUG CC-486
- DRUG ABI-007
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2011-11-29 |
| Est. Completion | 2015-11-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01478685
The ClinicalTrials.gov registry entry for NCT01478685 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 169 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT01478685 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01478685 about?
NCT01478685 is a clinical study titled "A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors". The purpose of the study is to evaluate the safety and to define the Maximal Tolerated Dose (MTD) or the Maximal Administered Dose (MAD) of oral azacitidine as a single agent and in combination with carboplatin (CBDCA) or paclitaxel protein bound particles (ABI-007,ABX) in subjects with relapsed or ...
What is the current status of trial NCT01478685?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 169 participants. The study started on 2011-11-29. Estimated completion is 2015-11-17.
What interventions are being tested in trial NCT01478685?
The interventions under investigation include: Carboplatin (DRUG), CC-486 (DRUG), ABI-007 (DRUG).
Who is sponsoring clinical trial NCT01478685?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.